Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Margetuximab-cmkb
Synonyms
Therapy Description

Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Margetuximab-cmkb Margenza MGAH22|MGAH-22 HER2 (ERBB2) Antibody 76 Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01828021 Phase II Margetuximab-cmkb Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer Completed USA 0
NCT01148849 Phase I Margetuximab-cmkb Safety Study of MGAH22 in HER2-positive Carcinomas Completed USA 1
NCT02492711 Phase III Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab-cmkb Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Completed USA | POL | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT 3


Additional content available in CKB BOOST